Avadel Pharmaceuticals Announces Upcoming Investor Attendance
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a pioneering biopharmaceutical firm, is dedicated to revolutionizing healthcare by crafting transformative medications. As part of their commitment to engaging with the investment community, the company has scheduled several important investor conferences that will feature discussions with key management personnel.
Details on the Upcoming Conferences
The first of these notable gatherings is the 2025 Wells Fargo Healthcare Conference. Avadel representatives will participate in a fireside chat on Friday, September 5 at 11:00 a.m. ET. This event represents a fantastic opportunity for discussions surrounding the company's strategic direction and innovative projects.
Insights at the Morgan Stanley Conference
Following this, the team will also contribute to the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. ET. Attending industry conferences such as these allows Avadel to highlight its groundbreaking research and development efforts.
H.C. Wainwright's Investment Opportunity
Next up is the H.C. Wainwright 27th Annual Global Investment Conference. Avadel will be featured in a fireside chat scheduled for Wednesday, September 10 at 9:30 a.m. ET. This engaging event aims to connect Avadel with potential investors and give an in-depth look at their operational strategies.
Webcasts and Future Access
Investors interested in following these discussions can access live webcasts of the events, including recorded versions which will be available on Avadel’s Investor Relations website. The archived webcasts will remain accessible for 90 days after each conference date, ensuring all stakeholders have the opportunity to stay updated on these significant developments.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc is committed to advancing medicine by developing innovative therapies that meet unmet clinical needs. With a focus on patient challenges, their standout product, LUMRYZ™, has achieved FDA approval as the first once-at-bedtime oxybate, aimed at treating cataplexy and excessive daytime sleepiness in patients aged seven years and older suffering from narcolepsy. This achievement exemplifies Avadel's dedication to enhancing patient care through innovation.
Contact Information for Interested Parties
For inquiries, interested parties can reach out to:
Investor Relations
Austin Murtagh
Precision AQ
Email: Austin.murtagh@precisionaq.com
Phone: (212) 698-8696
Media Outreach
Alyssa Ramirez
Real Chemistry
Email: aramirez@realchemistry.com
Frequently Asked Questions
1. What are the key events Avadel Pharmaceuticals will attend?
Avadel Pharmaceuticals will be attending the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.
2. How can investors access the conference details?
A live webcast of each event will be available on Avadel's Investor Relations website, along with archived recordings for 90 days post-conference.
3. What is LUMRYZ™ by Avadel Pharmaceuticals?
LUMRYZ™ is a novel medication approved by the FDA for treating cataplexy and excessive daytime sleepiness in narcolepsy patients aged seven and older.
4. Who should I contact for investor inquiries at Avadel?
For investor inquiries, contact Austin Murtagh at Precision AQ via email at Austin.murtagh@precisionaq.com.
5. What is Avadel's mission?
Avadel is dedicated to transforming lives through innovative medications that address pressing healthcare challenges faced by patients.